Image: AI-generated editorial illustration
Zus Health said on November 10, 2026, that it raised a $33 million Series B led by Drive Capital to expand its intelligent patient record platform, national healthcare data network, and AI-powered clinical workflows. The round brings the Boston-based healthcare infrastructure company’s total capital raised to more than $100 million.
What did Zus Health announce on November 10?
Zus Health announced a $33 million Series B financing on November 10, 2026, and said the new capital will be used to continue building its intelligent patient record platform, expand its national healthcare data network, and add more AI-powered clinical workflows. The company said the financing brings its total capital raised to more than $100 million.
The round was led by Drive Capital, with new participation from Sanofi Ventures, HealthX Ventures, and Alumni Ventures. Existing investors Andreessen Horowitz (a16z), F-Prime, Maverick Ventures, and JAZZ Venture Partners also returned.
Zus said demand for connected patient information has come from value-based care organizations, digital health companies, provider organizations, and innovators in diagnostics and precision medicine. The company said its common platform lets healthcare organizations develop and deploy applications without rebuilding the underlying data infrastructure for each use case.
What does Zus's platform do?
Zus says its approach centers on an intelligent, continuously updated patient record that serves as a shared foundation for healthcare applications. The company describes the Zus Aggregated Profile as a unified, longitudinal patient record assembled from fragmented clinical information.
Its network connects across EHR networks, pharmacy data, care event notifications, laboratories, and other clinical sources. Zus said that nationwide network supported more than 110 million networked transactions in August 2026.
The company also said its platform supports workflows including pre-visit preparation, transitions of care, risk adjustment, quality gap closure, and population health management. Goodwin said it advised Zus on the financing and described the company as serving providers, value-based care organizations, payers, life sciences companies, and digital health companies through its nationwide data network, platform, and intelligent workflows.
How is Zus using AI in its product?
AI appears to be one of the company’s main product bets. Zus said its clinical intelligence capabilities include AI-powered Generated Patient Summaries, which help transform fragmented records into information care teams can use more efficiently and confidently.
Zus said its AI-native clinical platform generated 39 million evidence citations year-to-date across its solutions. The company also said it supports workflows including pre-visit preparation, transitions of care, risk adjustment, quality gap closure, and population health management.
The company said those workflow capabilities are part of a broader effort to let healthcare organizations build tailored applications on top of its data infrastructure. It identified three strategic priorities for the new funding: advancing its intelligent platform, expanding its national healthcare data network, and enabling more healthcare workflows.
What should founders watch next?
Zus said the Series B proceeds are focused on those three priorities, including investments in AI-powered clinical intelligence, broader connectivity, improved record freshness, and more applications across value-based care, specialty care, and other use cases. The company also said it has HITRUST certification and announced its candidacy to become a Qualified Health Information Network under TEFCA in August 2026.
Founded in 2021, Zus was created by Jonathan Bush, who is also CEO, according to Business Insider Markets. The financing brings the Boston-based company’s total capital raised to more than $100 million.
Citybiz reported that Zus did not disclose valuation, revenue, or investor ownership stakes in the round. Goodwin said the legal team on the deal was led by Dave Cappillo, Katie Hand, Meggie Hickey, Paul Rosie, Katie Adams, and Adam DiTullio.
Sources
- Zus Health Raises $33 Million in Series B Funding to Accelerate the Next Generation of Connected Healthcaremarkets.businessinsider.com· Business Insider Markets
- Zus Health Raises $33M Series Bthesaasnews.com· The SaaS News
- Goodwin Advises Zus Health on Its $33 Million Series B Financinggoodwinlaw.com· Goodwin
- Zus Health Raises $33 Million Series B to Expand AI-Powered Healthcare Data Platformcitybiz.co· CitybizUnverified URL



